Inclusion Criteria:  Informed consent and willing to complete the study according to the protocol. Age ≥ 18 years and ≤ 75 years, and there is no limit on the gender ECOG performance scale 0-1; Diagnosed as pancreatic adenocarcinoma by histology and cytology; Treatment of patients with advanced metastatic pancreatic cancer who have failed with NG (Nab-paclitaxel + gemcitabine) regimen(The disease progresses during the course of treatment or within 6 months after the end of treatment, with clear imaging evidence; this does not include patients with intolerable toxicity)；  Baseline blood routine and biochemical indexes meet the following criteria:  Blood routine examination criteria must be met: (no blood transfusion within 14 days)  HB≥90g/L； ANC≥1.5×109/L； PLT≥100×109/L.  Biochemical tests are subject to the following criteria:  BIL <1.25xULN ； ALT and AST<2.5ULN； Serum creatinine. Less than 1.5 times the upper limit of normal value, Endogenous creatinine clearance>60ml/min ( Cockcroft-Gault formula). Albumin≥28g/L.  Blood coagulation indexes are subject to the following criteria:  Prothrombin time (PT) and international normalized ratio (INR) ≤1.5 × ULN; Activated partial thromboplastin time（APTT）≤1.5 × ULN. According to the standard of RECIST 1.1, there is at least one imaging measurable lesion; Life expectancy ≥ 3 months; Patients and their families were willing to cooperate with follow-up.  Exclusion Criteria:  Diagnosis of malignant diseases other than pancreatic cancer within 5 years prior to first administration (excluding cured skin basal cell carcinoma, squamous carcinoma of the skin, and/or resected carcinoma in situ); Medical conditions that affect absorption, distribution, metabolism, or clearance of the study drug (e.g., severe vomiting, chronic diarrhea, intestinal obstruction, absorption disorders, etc.); Patients with brain metastases or pial metastases; Patients with a clear past history of neurological or psychiatric disorders, including epilepsy or dementia; Comorbidities (e.g., severe or uncontrolled hypertension, severe diabetes, and/or thyroid disease) that, in the investigator's judgment, seriously endanger patients' safety or prevent them from completing the study; The patient was currently participating in an interventional clinical study or had been treated with another study drug or study device in the 4 weeks prior to initial dosing; The patient had a history of organ transplantation; Concurrent administration of drugs that may prolong QTc and/or induce Tdp; Patients also take drugs that affect drug metabolism; HIV infection or acute or chronic viral hepatitis (hbSAG positive, HBV-DNA load ≥500IU/ml and/or HCV antibody positive); Excluded patients with serious cardiovascular disease, including grade ≥II cardiac dysfunction (NYHA criteria); Patients with severe gastrointestinal dysfunction (bleeding, infection, obstruction, or diarrhea greater than grade 1) were excluded; Patients with abnormal coagulation function, bleeding tendency, or receiving thrombolytic or anticoagulant therapy were excluded; Patients with a severe arterial thromboembolism event within 6 months were excluded; Excluding women who are pregnant or breast-feeding.